🟢 Corcept Therapeutics is trading 5.7% up today after a strong Q2 earnings beat and guidance hike

Corcept Therapeutics is trading 5.7% up at $121.00 in after-hours trading, extending a sharp rally following its Q2 2026 financial results.

• The company reported a significant Q2 beat with revenue rising 32% year-over-year to $256.1 million and EPS reaching $0.36.
• Management raised full-year revenue guidance to a range of $1.1–$1.2 billion, fueled by the strong launch of oncology drug Lifyorli and continued growth in its Cushing’s syndrome franchise.